Therapy deficit
doi: 10.1038/489473b
doi: 10.1038/489473b
doi: 10.1038/489473a
doi: 10.1038/489474a
doi: 10.1038/489482a
doi: 10.1038/489485a
doi: 10.1038/489481a
doi: 10.1038/489484a
doi: 10.1038/489486a
doi: 10.1038/489488a
doi: 10.1038/489487a
doi: 10.1038/nature11487
doi: 10.1038/nature11488
doi: 10.1038/nature11486
doi: 10.1038/489508a
doi: 10.1038/489510a
doi: 10.1038/489511a
Evolutionary novelties have been important in the history of life, but their origins are usually difficult to examine in detail. We previously described the evolution of a novel trait, aerobic citrate utilization (Cit
doi: 10.1038/nature11514
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers.
doi: 10.1038/nature11404
Immune recognition of protein antigens relies on the combined interaction of multiple antibody loops, which provide a fairly large footprint and constrain the size and shape of protein surfaces that can be targeted. Single protein loops can mediate extremely high-affinity binding, but it is unclear whether such a mechanism is available to antibodies. Here we report the isolation and characterization of an antibody called C05, which neutralizes strains from multiple subtypes of influenza A virus, including H1, H2 and H3. X-ray and electron microscopy structures show that C05 recognizes conserved elements of the receptor-binding site on the haemagglutinin surface glycoprotein. Recognition of the haemagglutinin receptor-binding site is dominated by a single heavy-chain complementarity-determining region 3 loop, with minor contacts from heavy-chain complementarity-determining region 1, and is sufficient to achieve nanomolar binding with a minimal footprint. Thus, binding predominantly with a single loop can allow antibodies to target small, conserved functional sites on otherwise hypervariable antigens.
doi: 10.1038/nature11414
doi: 10.1038/nature11447
doi: 10.1038/nature11459
doi: 10.1038/nature11449
doi: 10.1038/nature11445
doi: 10.1038/nature11440
doi: 10.1038/nature11335
doi: 10.1038/nature11349
doi: 10.1038/nature11499
doi: 10.1038/nature11371
doi: 10.1038/nature11368
doi: 10.1038/nature11355
doi: 10.1038/nature11353
doi: 10.1038/nature11354